[An early phase II study of autologous peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission. Japan Blood Cell Transplantation Study Group]

• Abstract: We performed a multicenter, an early phase II clinical trial to evaluate the feasibility, safety and efficacy of myeloablative therapy supported by autologous peripheral blood stem cell transplantation (auto-PBSCT) for the treatment of acute myelogenous leukemia (AML) in first remission. A total of 105 patients were enrolled in the study, and 56 patients in first complete remission received auto-PBSCT. The median age was 44 years. Of the 56 patients, 34 (60.7%) had M2 or M3 AML by the French-American-British Classification system. The median concentration of infused CD34+ cells was 2.3 x 10(6)/kg by recipient body weight. Median days to reach an absolute neutrophil count > 500/microliter and a platelet count > 20000/microliter were 14 and 16, respectively. The median disease-free survival rate was estimated to be 62.0% at a median follow-up time of 534 days. Although the study enrolled a small number of patients and the follow-up period was relatively short, the preliminary results were encouraging and indicated that myeloablative chemotherapy with auto-PBSCT is feasible and can be performed safely as a post-remission therapy for AML. A prospective randomized clinical trial of auto-PBSCT versus standard chemotherapy alone will be necessary to assess the efficacy of high-dose therapy facilitated by auto-PBSCT as a post-remission therapy for AML.
• Authors: F Kawano, T Kiyokawa, K Shinagawa, K Takenaka, K Imajo, S Hayashi, Y Hirota, H Ohno, H Tsuda, H Gondo, T Shibuya, S Hisano, M Harada, M Ogawa, F Takaku
• Journal: [Rinshō ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 40 Issue 10 Pg. 1051-7 (Oct 1999) ISSN: 0485-1439 [Print] JAPAN
• PMID: 10565221 (Publication Type: Clinical Trial, Clinical Trial, Phase II, English Abstract, Journal Article, Multicenter Study)

Topics

• Adolescent
• Adult
• Aged
• Disease-Free Survival
• Female
• Follow-Up Studies
• Hematopoiesis
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myeloid, Acute (blood, therapy)
• Male
• Middle Aged
• Remission Induction
• Transplantation, Autologous